AGM (31 - 0), page-2

A very extensive and mainly accurate report. However I got a slightly different message on two issues. My take was that the results from the Nadilol oral trial in smoking cessation would have interim results in two to four weeks and final results in first half 2015. I agree that the executives seemed very excited about the interim results but they were emphasised as interim. The presentation shows likewise. Second the dosage for patients with some renal symptoms is 30 mg, not 100 mg. Not big issues but I like accuracy. As I understand the protocol on Cpn10, they have to have a successful (adverse incident free) trial at a lower dose before proceeding to a higher dose and have to have a successful trial in mild disease before proceeding to a trial in patients with amore advanced condition at the same dose. So they have to have successfully completed a trial at 30 mg in mild disease before proceeding to patients with more advanced disease or a trial at higher doses.